SUBSCRIBE
SUBSCRIBE
News   Drug Development

Isis Pharmaceuticals, Inc. Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium

October 1, 2007 | 
1 min read

CARLSBAD, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS - News) announces the following webcast:

Clinical research Phase II
MORE ON THIS TOPIC
Roche's signage at its office in France
Immunology & inflammation
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
December 3, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Novartis' logo outside its building in S
Huntington’s disease
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
December 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Colorful DNA molecule. Structure of the genetic code. Genetic Syndrome and Genetic Disorder, 3D illustration of science concept.
Gene therapy
Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies
December 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
December 2, 2024
 · 
4 min read
 · 
Tristan Manalac